---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-119486"
form_type: "8-K"
ticker: "ELAN"
cik: "0001739104"
company_name: "Elanco Animal Health Inc"
filed_at: "2025-12-09T23:59:59+00:00"
generated_at: "2026-05-16T13:48:43.474616+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elanco announces restructuring plan and three-year financial outlook; Befrena technical sections complete

## Summary
- Restructuring: ~300 jobs eliminated, ~300 shifted; ~$175M pretax charge (~$130M cash); closure of Kansas City implant facility, partial exit from Monheim Germany.
- Three-year outlook: mid-single digit revenue growth, high-single digit adj. EBITDA growth, low double-digit adj. EPS growth starting 2026.
- Befrena (IL-31 mAb) technical sections complete; administrative review underway; launch expected H1 2026.
- Innovation revenue ~$1.1B in 2026; 5-6 blockbuster potential approvals expected 2026-2031.
- Elanco Ascend: $200-250M adjusted EBITDA savings by 2030; ~$25M in 2026, ~$60M in 2027.

## SEC filing metadata
- accession: 0001104659-25-119486
- form_type: 8-K
- ticker: ELAN
- cik: 0001739104
- company_name: Elanco Animal Health Inc
- filed_at: 2025-12-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739104/000110465925119486/0001104659-25-119486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739104/000110465925119486/tm2533048d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-119486
- JSON: https://secwatch.observer/filing/0001104659-25-119486.json
- Plain text: https://secwatch.observer/filing/0001104659-25-119486.txt

## Key facts
- Restructurings & Charges
  Elanco Animal Health Inc announced a restructuring with charges of approximately $175 million affecting global headcount reduction and closure of Kansas City, Missouri implant facility and exit from portion of Monheim, Germany facility (approximately 300 employees, plus an approximate 300 employees whose positions will be replaced).
  - Type: restructuring
  - Charge: approximately $175 million
  - Affected area: global headcount reduction and closure of Kansas City, Missouri implant facility and exit from portion of Monheim, Germany facility
  - Headcount: approximately 300 employees, plus an approximate 300 employees whose positions will be replaced
  source text: On December 5, 2025, the Board of Directors of Elanco Animal Health Incorporated (the “Company”) authorized a restructuring plan with respect to its workforce (the “Restructuring Plan”) to support margin expansion, optimize the Company’s footprint, and further invest in innovation. The Restructuring Plan will result in a global headcount reduction of approximately 300 employees, plus an approximate 300 employees whose positions will be replaced with positions in growth areas or in lower-cost geographies. Expected pretax charges associated with the Restructuring Plan total approximately $175 million, the majority of which will be incurred in 2025, including an estimated $130 million of cash-based costs, most of which is expected to be paid in the next 2 years, and an estimated $45 million of non-cash asset impairment charges primarily related to the Company’s closure of its Kansas City, Missouri implant facility and exit from a portion of its Monheim, Germany facility.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739104/000110465925119486/0001104659-25-119486-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.